TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05602194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given standard of care calaspargase pegol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calaspargase Pegol
Description: Given standard of care calaspargase pegol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Given PO or IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given standard of care pegaspargase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given standard of care pegaspargase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06181240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy
Description: Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
Study: NCT05567614

Intervention type: RADIATION
Intervention: Liver Fibroscan
Description: Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
Study: NCT05060900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligament Reconstruction with Allograft Ligament
Description: Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
Study: NCT06257290

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: at Day 1 - date of patient inclusion at time of VTE diagnosis

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: at 6 months (in the patient follow-up)
Study: NCT06589596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-58067
Description: Planned doses administered on specified days per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-58067
Description: Planned doses administered on specified days per protocol.
Study: NCT05282485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Synbiotic (2'-FL HMO + B. infantis probiotics)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study: NCT05327699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
Study: NCT05163951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: trabeculectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPI+GSL+GT
Description: Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
Study: NCT05323864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Hypoxia
Description: Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
Study: NCT05829148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06367452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alginate + sodium bicarbonate + magaldrate + simeticone
Description: Take an oral suspension of 10 mL 30 minutes after the ingestion of a standardized breakfast
Study: NCT05469009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Model 4000 Type 2
Description: The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening
Study: NCT05372666

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard white bread
Description: Bread to be consumed within 10 minutes after 10h fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental white bread
Description: Bread to be consumed within 10 minutes after 10h fasting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting
Study: NCT05886426

Intervention type: DIAGNOSTIC_TEST
Intervention: 4DCT wrist and standard CT wrist
Description: Dynamic CT aquistion of wrist during movement and standard static wrist CT

Intervention type: DIAGNOSTIC_TEST
Intervention: 4DCT wrist and standard CT wrist
Description: Dynamic CT aquistion of wrist during movement and standard static wrist CT

Intervention type: DIAGNOSTIC_TEST
Intervention: 4DCT wrist and standard CT wrist
Description: Dynamic CT aquistion of wrist during movement and standard static wrist CT
Study: NCT05872178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omegia® Softgel -B
Description: How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omegia® Softgel -A
Description: How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
Study: NCT05452226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation (NMES)
Description: Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
Study: NCT06222749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Description: 24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Description: 24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Description: 24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Description: 24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo administration
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo administration
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo administration
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo administration
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.
Study: NCT05436002

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: With Cross-linked Hyaluronic Acid
Description: Without Cross-linked Hyaluronic Acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: With Cross-linked Hyaluronic Acid
Description: Without Cross-linked Hyaluronic Acid
Study: NCT04661878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Resources
Description: The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Resources
Description: The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring and habit formation
Description: The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting and action planning
Description: The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
Study: NCT06234163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned intervention
Description: Enteral and parenteral nutrition training was given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature was sent to ten experts in the field. and content validity was done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition.
Study: NCT05087134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Choline
Description: 11C-Choline were injected into the patients before the PET/CT scans
Study: NCT05352386

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary computed tomography angiography (CCTA)
Description: Participants undergo coronary computed tomography angiography (CCTA)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary computed tomography angiography (CCTA)
Description: Participants undergo coronary computed tomography angiography (CCTA)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary computed tomography angiography (CCTA)
Description: Participants undergo coronary computed tomography angiography (CCTA)
Study: NCT06041061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
Study: NCT06767072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Multichannel interventions
Description: To ensure the feasibility of the intervention, the intervention will be designed by an interdisciplinary team including academic researchers from different specialties (experts in the fields of community health, psychiatry health, and nutrition), as well as 3 research assistants.~The designing process for each individual in the intervention group involved the following 4 subsequent steps: (1) intervention nurses assess HBM constructs, which are used to collect data on each unique perception regarding overweight(Saghafi-Asl et al., 2020). (2) data are reviewed, identified, and summarized by the interdisciplinary team; (3) the interdisciplinary team then creates an intervention plan based on the summarized needs and (4) the intervention plan will be shared with the participant to ensure collaboration.~The intervention will adopt the strategies of the Diabetes Prevention Program (DDP) (The Diabetes Prevention Program (DPP), 1996).
Study: NCT06771206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Owlet pulse oximeter neonatal accuracy validation
Description: This study specifically evaluates the Owlet pulse oximetry sensor, which is specifically designed and FDA cleared for for infants, and whose accuracy is specifically being validated in the neonate population.
Study: NCT06772337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital cardiac rehabilitation
Description: Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Treatment
Description: Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Out-of-hospital cardiac rehabilitation: Receiving conventional treatment and secondary prevention drugs recommended by current guidelines, nutritional diet and lifestyle guidance, and establishing a WeChat group as a postoperative follow-up contact method.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
Study: NCT05232890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Datterino tomato purée from hydroponic technology
Description: Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Datterino tomato puree from conventional cultivation
Description: Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
Study: NCT05753800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTORUS
Description: Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
Study: NCT05567341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-control
Description: A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
Study: NCT05427656

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F] TRACK
Description: We propose to use the radiotracer \[18F\] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq \[18F\] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes (\[18F\] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for \[18F\] TRACK after a transmission scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Arterial Input Function
Description: The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
Study: NCT05141864

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acmella oleracea gel
Description: Study group will use Acmella oleracea gel during the digital rectal examination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2 % Topical Cream
Description: Control group will use lidocaine 2% gel during the digital rectal examination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound gel
Description: Control group will use ultrasound gel during the digital rectal examination.
Study: NCT05681208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week.
Study: NCT06346548

Intervention type: OTHER
Intervention: oral photography
Description: The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner

Intervention type: OTHER
Intervention: oral photography
Description: The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner

Intervention type: OTHER
Intervention: oral photography
Description: The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner